Collectively, these data demonstrate that BRCA2 deficiency significantly increases tumor sensitivity to V66-exatecan, promoting tumor regression and significantly improving survival, highlighting the potential of V66-exatecan as an effective therapeutic strategy for BRCA2-deficient cancers. This evidence concerns the gene BRCA2 and neoplasm.